⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SMMT News
Summit Therapeutics Inc. Common Stock
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
businesswire.com
SMMT
Summit Therapeutics to Present at Upcoming Investor Conferences
businesswire.com
SMMT
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
businesswire.com
SMMT
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
businesswire.com
SMMT
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
businesswire.com
SMMT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
prnewswire.com
SMMT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
prnewswire.com
SMMT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
prnewswire.com
SMMT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
prnewswire.com
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
SMMT